Abstract
The paper provides an overview of modern genetically engineered biological agents (GEBAs) used in the treatment of rheumatoid arthritis (RA) in the Russian Federation. The spectrum of medicinal agents of this group used in the Novgorod region has been analyzed. The analysis of treatment regimens of 68 patients demonstrates high efficiency of combination therapy of GEBAs and disease modifying anti-rheumatic drugs due to a decrease in the activity of the process of more than 78 % of the patients and to achieving remission of 2.9 % of them. It is indicated that GEBAs therapy requires careful screening procedures of patients, exclusion of infectious processes, cancer and severe pathology of internal organs. The reasons for the difficulties in achieving remission against the background of GEBAs therapy of the observed patients, as well as complications arising during the treatment, are given.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
